OverviewSuggest Edit

Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine. It offers a diverse portfolio of cell-based product candidates with three programs in Phase 3 clinical studies. The Company's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes and kidney disease, orthopedic spine conditions, and cardiovascular disorders.

TypePublic
Founded2004
HQMelbourne, AU
Websitemesoblast.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2021)102
Share Price (Oct 2021)$1.6(-2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Mesoblast

Silviu Itescu

Silviu Itescu

Chief Executive Officer & Managing Director
Joseph R. Swedish

Joseph R. Swedish

Non-Executive Chairman
Josh Muntner

Josh Muntner

CFO
Shawn Cline Tomasello

Shawn Cline Tomasello

Non-Executive Director
Peter Howard

Peter Howard

Corporate Executive & General Counsel
Fred Grossman

Fred Grossman

Chief Medical Officer
Show more

Mesoblast Office Locations

Mesoblast has offices in Melbourne, New York and Singapore
Melbourne, AU (HQ)
Level 38/55 Collins St
Singapore, SG
21 Biopolis Rd
New York, NY, US
505 5th Ave Level 3
Show all (3)

Mesoblast Financials and Metrics

Mesoblast Revenue

Market capitalization (1-Oct-2021)

1.1b

Closing stock price (1-Oct-2021)

1.6
Mesoblast's current market capitalization is $1.1 b.
Show all financial metrics

Mesoblast Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Mesoblast Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Mesoblast Online and Social Media Presence

Embed Graph

Mesoblast News and Updates

Thinking about buying stock in Canoo, Cidara Therapeutics, Ford Motor, Mesoblast, or Reliance Global?

NEW YORK, Dec. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOEV, CDTX, F, MESO, and RELI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility

NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided…

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from the randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with mod…

Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy for bringing rexlemestrocel-L to patients in the United States (US) with chronic low back pain (C…

Mesoblast Operational Highlights and Upcoming Milestones

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the Company’s recent operational highlights, as well as upcoming milestones.
Show more

Mesoblast Frequently Asked Questions

  • When was Mesoblast founded?

    Mesoblast was founded in 2004.

  • Who are Mesoblast key executives?

    Mesoblast's key executives are Silviu Itescu, Joseph R. Swedish and Josh Muntner.

  • How many employees does Mesoblast have?

    Mesoblast has 102 employees.

  • Who are Mesoblast competitors?

    Competitors of Mesoblast include Celltex, AXON Neuroscience and Human Stem Cells Institute.

  • Where is Mesoblast headquarters?

    Mesoblast headquarters is located at Level 38/55 Collins St, Melbourne.

  • Where are Mesoblast offices?

    Mesoblast has offices in Melbourne, New York and Singapore.

  • How many offices does Mesoblast have?

    Mesoblast has 3 offices.